Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00889564 · ClinicalTrials.gov registry record · NA
HeRO Vascular Access Device Bacteremia Study
A NA study, sponsored by Merit Medical Systems.
- Completed
- Registry status
- NA
- Development phase
- 38
- Enrollment target
NCT00889564: Completed NA study, sponsored by Merit Medical Systems.
NCT00889564 is a NA study that has completed, run by Merit Medical Systems. The registered enrollment target is 38 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00889564, a NA study, has completed, sponsored by Merit Medical Systems.
- COMPLETED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and effectiveness of the HeRO Vascular Access Device in access challenged (e.g., catheter-dependent) hemodialysis patients. It is hypothesized the bacteremia rate associated with the HeRO device will be lower than a historical literature control of tunneled dialysis catheters.
Interventions
- DEVICE HeRO Vascular Access Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2006-03 |
| Est. Completion | 2007-03 |
| Phase | NA |
What the finished NCT00889564 record still lists
NCT00889564 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which HeRO Vascular Access Device is the first listed.
NCT00889564 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00889564 about?
NCT00889564 is a clinical study titled "HeRO Vascular Access Device Bacteremia Study". The purpose of this study is to compare the safety and effectiveness of the HeRO Vascular Access Device in access challenged (e.g., catheter-dependent) hemodialysis patients. It is hypothesized the bacteremia rate associated with the HeRO device will be lower than a historical literature control of ...
What is the current status of trial NCT00889564?
This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2006-03. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00889564?
The interventions under investigation include: HeRO Vascular Access Device (DEVICE).
Who is sponsoring clinical trial NCT00889564?
This trial is sponsored by Merit Medical Systems, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00889564's enrollment target sits among peer trials
38 1538th of 2000 higher than 461 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia